Article

Ubiquitin-specific peptidase 46 (Usp46) regulates mouse immobile behavior in the tail suspension test through the GABAergic system.

Division of Biomodeling, Graduate School of Bioagricultural Sciences, Nagoya University, Nagoya, Japan.
PLoS ONE (impact factor: 4.09). 01/2012; 7(6):e39084. DOI:10.1371/journal.pone.0039084 pp.e39084
Source: PubMed

ABSTRACT The tail suspension test (TST) is widely recognized as a useful experimental paradigm for assessing antidepressant activity and depression-like behavior. We have previously identified ubiquitin-specific peptidase 46 (Usp46) as a quantitative trait gene responsible for decreasing immobility time in the TST in mice. This Usp46 mutation has a 3-bp deletion coding for lysine in the open reading frame, and we indicated that Usp46 is implicated in the regulation of the GABAergic system. However, it is not known precisely how the immobile behavior is regulated by the GABAergic system. Therefore, in the present study, we examined whether the immobility time is influenced by drugs affecting the action mediated by GABA(A) receptor using both 3-bp deleted (the Usp46 mutant) and null Usp46 (Usp46 KO) mice. Nitrazepam, an agonist at the benzodiazepine-binding site of the GABA(A) receptor, which potentiates the action of GABA, produced a dose-dependent increase in TST immobility time in the Usp46 mutant mice without affecting general behaviors. The Usp46 KO mice exhibited short immobility times comparable to the Usp46 mutant mice, which was also increased by nitrazepam administration. The effects of nitrazepam in the Usp46 mutant and KO mice were antagonized by flumazenil. These results indicate that the 3-bp deleted Usp46 mutation causes a loss-of-function phenotype, and that the GABA(A) receptor might participate in the regulation of TST immobility time.

0 0
 · 
0 Bookmarks
 · 
48 Views
  • Article: Depression: a new animal model sensitive to antidepressant treatments.
    Nature 05/1977; 266(5604):730-2. · 36.28 Impact Factor
  • Article: The tail suspension test: a new method for screening antidepressants in mice.
    [show abstract] [hide abstract]
    ABSTRACT: A novel test procedure for antidepressants was designed in which a mouse is suspended by the tail from a lever, the movements of the animal being recorded. The total duration of the test (6 min) can be divided into periods of agitation and immobility. Several psychotropic drugs were studied: amphetamine, amitriptyline, atropine, desipramine, mianserin, nomifensine and viloxazine. Antidepressant drugs decrease the duration of immobility, as do psychostimulants and atropine. If coupled with measurement of locomotor activity in different conditions, the test can separate the locomotor stimulant doses from antidepressant doses. Diazepam increases the duration of immobility. The main advantages of this procedure are the use of a simple, objective test situation, the concordance of the results with the validated "behavioral despair" test from Porsolt and the sensitivity to a wide range of drug doses.
    Psychopharmacologia 02/1985; 85(3):367-70. · 4.08 Impact Factor
  • Article: In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice.
    [show abstract] [hide abstract]
    ABSTRACT: The ability to modify mice genetically has been one of the major breakthroughs in modern medical science affecting every discipline including psychiatry. It is hoped that the application of such technologies will result in the identification of novel targets for the treatment of diseases such as depression and to gain a better understanding of the molecular pathophysiological mechanisms that are regulated by current clinically effective antidepressant medications. The advent of these tools has resulted in the need to adopt, refine and develop mouse-specific models for analyses of depression-like behavior or behavioral patterns modulated by antidepressants. In this review, we will focus on the utility of current models (eg forced swim test, tail suspension test, olfactory bulbectomy, learned helplessness, chronic mild stress, drug-withdrawal-induced anhedonia) and research strategies aimed at investigating novel targets relevant to depression in the mouse. We will focus on key questions that are considered relevant for examining the utility of such models. Further, we describe other avenues of research that may give clues as to whether indeed a genetically modified animal has alterations relevant to clinical depression. We suggest that it is prudent and most appropriate to use convergent tests that draw on different antidepressant-related endophenotypes, and complimentary physiological analyses in order to provide a program of information concerning whether a given phenotype is functionally relevant to depression-related pathology.
    Molecular Psychiatry 05/2004; 9(4):326-57. · 13.67 Impact Factor

Full-text

View
1 Download
Available from

Keywords

3-bp deleted Usp46 mutation causes
 
3-bp deletion coding
 
antidepressant activity
 
decreasing immobility time
 
GABAergic system
 
general behaviors
 
immobility time
 
KO mice
 
nitrazepam administration
 
null Usp46
 
open reading frame
 
quantitative trait gene responsible
 
tail suspension test
 
TST immobility time
 
ubiquitin-specific peptidase 46
 
useful experimental paradigm
 
Usp46 KO mice exhibited short immobility times comparable
 
Usp46 mutant
 
Usp46 mutant mice
 
Usp46 mutation